Chinese chemical industry news

3 March 2026

GSK Finalizes RAPT Therapeutics Acquisition

GSK acquires ozureprubart, a potential long-acting anti-IgE therapy for food allergies, with phase IIb data expected in 2027. The deal is valued at $2.2 billion.

How does the Chinese chemical industry perform?

Find out with chemXplore Analytics